The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A review of the management of antidepressant discontinuation symptoms
Open accessAbstract
Strong evidence supports the existence of a discontinuation syndrome following the withdrawal of antidepressant medication, particularly second-generation antidepressants. The syndrome is a common phenomenon and guidance as to best avoid the symptoms is essential for both practitioners and patients. The current study reviewed the available literature on the best methods of discontinuation for antidepressants in order to avoid or prevent the occurrence of any unpleasant side effects associated with antidepressant withdrawal. Accordingly, an electronic search of the PubMed/MedLine database and Google Scholar was conducted to find relevant literature published within the last 10 years. From this, 18 related articles were identified; five clinical studies, one case series, one consensus panel’s recommendations and 11 literature reviews. Of the articles reviewed there is a general consensus as to tapering the drug slowly over a period of weeks or months. Also, in those patients who experience severe symptoms the drug should be reinstated and discontinued more gradually. The discontinuation syndrome does not occur as frequently or severely with longer-acting agents such as fluoxetine and therefore it is recommended that switching to this drug prior to withdrawal may be advisable. The articles reviewed also emphasize the need for patient education and reassurance throughout the discontinuation process. One in particular adds that cognitive behavioural therapy may be a useful tool in easing the patients’ distress. However, this review highlights the lack of controlled data to support the available guidelines. Furthermore, the guidance which is available is somewhat conflicting. Research approaches should address this issue as well as develop appropriate methods of withdrawal for specific drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results are consistent with the findings of a previous review reporting consensus about tapering antidepressants slowly over a period of weeks or months to avoid withdrawal symptoms (Wilson 2015).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Wilson 2015
The cited source says what the claim attributes to it.
In the citing paper
“The characteristics of the discontinuation syndrome have been linked to the half-life of a given SSRI, which can explain the low levels of fluoxetine discontinuation syndrome here identified (Wilson and Lader, 2015)”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Wilson and Lader, 2015
In the citing paper
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
In the citing paper
“As PWS from antidepressants has been so poorly recognized, the literature is largely silent about its treatment.35,39”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Depression: A Global Public Health Concern: (517532013-004)
Marcus, M., Yasamy, M. T., van Ommeren, M. V., Chisholm, D., & Saxena, S. (2012) · PsycEXTRA Dataset · doi:10.1037/e517532013-004 · Cited by 985
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 2×
“At present, the most recent antidepressant guidelines advise this method and recommend a minimum period of a 4-week taper following long-term treatment, preferably over months for a planned withdrawal of antidepressant medication [Cleare et al. 2015].”
BackgroundBirth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Initiatives to Promote the Discovery of Drugs to Improve Cognitive Function in Severe Mental Illness
Marder, S. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0706e03 · Cited by 218
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 1×
“In 1997, Zajecka and colleagues defined the SSRI discontinuation syndrome as a cluster of symptoms following the discontinuation of a SSRI, not due to other factors [Zajecka et al. 1997].”
BackgroundSelective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Research works printed but not linked: 13
- Black K., 2000, J Psychiatry Neurosci, 25, 255
- Coryell W. (2013) Depressive disorders. Merck Manuals Professional Edition. Available at: http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html#v1028131 (accessed 25 August 2014).
- Gartlehner G., 2011, Comparative Effectiveness Reviews
- Groot P., 2013, Tijdschr Psychiatr, 55, 789
- Haddad P., 2007, APT, 13, 447
- Joffe R., 2006, J Psychiatry Neurosci, 31, 11
- Lieberman J., 2003, J Clin Psychiatry, 5, 6
- Muzina D., 2010, Curr Psychiatry, 9, 50
- Renoir T., 2013, Front Pharmacol, 16, 45
- Schatzberg A., 2006, J Clin Psychiatry, 67, 27
- Schatzberg A., 1997, J Clin Psychiatry, 58, 23
- Warner C., 2006, Am Fam Physician, 74, 449
- Wiese B., 2011, BCMJ, 53, 341
Cited by
Samal, K., Mahapatra, S., & Hibzur Ali, M. (2022) · Energy Nexus · doi:10.1016/j.nexus.2022.100076 · Cited by 778
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice
Francescangeli, J., Karamchandani, K., Powell, M., & Bonavia, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092288 · Cited by 159
Depression and Its Phytopharmacotherapy—A Narrative Review
Dobrek, Ł., & Głowacka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054772 · Cited by 196
Metadata
- Authors
- Wilson, E., & Lader, M.
- Affiliations
- King's College London (GB)
- Corresponding author
- Wilson, Emma
- ORCID
- Wilson, Emma
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-10-28
- Volume
- 5
- Issue
- 6
- Pages
- 357-368
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4722507
- OpenAlex
- W2296227733
- Cited by
- 103
- References
- 52
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 14 · 2019: 14 · 2018: 15 · 2017: 12 · 2016: 4
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant discontinuation syndrome, antidepressant discontinuation, second-generation antidepressants, gradual tapering, fluoxetine, patient education, cognitive behavioral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of the management of antidepressant discontinuation symptoms. https://app.cochat.ai/papers/10.1177/2045125315612334
- The paper
- Wilson, E., & Lader, M. (2015). A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125315612334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.